Silo Pharma (SILO) Asset Writedowns and Impairment (2017 - 2026)
Silo Pharma (SILO) posted Asset Writedowns and Impairment of $29911.0 for Q1 2026, up 249.56% sequentially from -$20000.0 in Q1 2022.
Silo Pharma (SILO) Asset Writedowns and Impairment (2017 - 2026) Analysis & Trends
Silo Pharma has reported Asset Writedowns and Impairment for 6 years, with the latest figure at $29911.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $29911.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29911.0 (changed N/A YoY) and the FY2025 annual result came in at $39916.0, changed N/A from the prior year.
- Asset Writedowns and Impairment rose to $29911.0 in Q1 2026 per SILO's latest filing, from -$20000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $29911.0 in Q1 2026 and troughed at -$20000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,911.00 |
| Mar 31, 2026 | 29,911.00 |
| Mar 31, 2022 | -20,000.00 |
| Mar 31, 2022 | -20,000.00 |
| Dec 31, 2021 | -65,000.00 |
| Dec 31, 2021 | -65,000.00 |
| Sep 30, 2021 | -37,500.00 |
| Sep 30, 2021 | -37,500.00 |
| Jun 30, 2021 | -38,500.00 |
| Jun 30, 2021 | -38,500.00 |
| Mar 31, 2021 | -7,500.00 |
| Mar 31, 2021 | -7,500.00 |
| Dec 31, 2020 | 196,500.00 |
| Dec 31, 2020 | 196,500.00 |
| Dec 31, 2018 | 104,412.00 |
| Dec 31, 2018 | 104,412.00 |
| Dec 31, 2017 | 56,160.00 |
| Dec 31, 2017 | 56,160.00 |